Why 3billion Is Not a Genome Analysis Company

As part of our educational series on genetic testing for rare diseases, we’re addressing the most frequently asked questions from clinicians. Today, we’re answering one of the most important:

“How is 3billion different from other genome companies?”

It’s a fair question—and one that touches on the heart of what we do.

We Are Not a Genome Analysis Company

At 3billion, we’re often mistaken for a genome analysis company. But we are not in the business of just identifying variants.

Instead, we offer a clinical genetic diagnostics service built for physicians who need actionable answers, not just data files. Our mission is to help healthcare providers accurately diagnose patients with rare genetic disorders—quickly, precisely, and with full support.

Genome Analysis vs. Genetic Diagnosis: What’s the Difference?

Let’s break it down.

What Genome Analysis Companies Do

Most genome analysis companies provide data on which genetic variants exist in a patient’s DNA. This is known as variant calling and annotation—important steps, but only the beginning of the diagnostic process.

What 3billion Does

At 3billion, we deliver a complete clinical interpretation. We analyze the variants, connect them with patient symptoms (phenotypes), and identify the disease-causing variant(s) using a mix of advanced AI tools and expert clinical geneticist review.

We don’t just give you data—we give you answers.

From Sample to Diagnosis: The Process

Here’s what happens after you send us a sample for WES (Whole Exome Sequencing) or WGS (Whole Genome Sequencing):

Step 1: Variant Calling

We compare the patient’s DNA to a reference genome to identify genetic variants.

• WES typically identifies ~100,000 variants
• WGS can uncover over 5 million variants

Step 2: Variant Annotation

Each variant is annotated with information such as:

• Affected gene and protein impact
• Frequency in global populations
• Known disease associations

Step 3: Variant Interpretation

This is where we truly add value. We:

• Prioritize candidate variants using AI-driven pipelines
• Cross-reference clinical phenotype data
• Apply ACMG guidelines for pathogenicity classification
• Involve trained clinical geneticists in final review

The result? A clinically actionable genetic report, not a spreadsheet.

The 3billion Advantage: Clinical-Grade Genetic Diagnostics

At 3billion, we eliminate this burden. Our platform provides:

• A fully automated, AI-powered diagnostic pipeline
• Expert-reviewed clinical reports
• A user-friendly, physician-focused interface

Want to Learn More?

If you’re ready to move beyond data and focus on diagnosis, we’d love to show you how 3billion can support your work.

Click “Contact Us” to speak with our team and explore our clinical-grade WES/WGS services tailored to rare disease diagnostics.